Dr. Keophiphath, founder and CEO of DIVA Expertise, brings a strong scientific and academic foundation to her role at the forefront of biotechnology. She began her academic journey with an engineering degree in nutraceuticals, health food, and nutricosmetics. She later earned a doctorate in physiology and physiopathology, focusing her research on chronic, low-grade inflammation in adipose tissue.

Dr. Keophiphath’s expertise is further enriched by her training as a clinical trial investigator. This comprehensive educational foundation has equipped her with an in-depth understanding of adipose tissue and enables her to bridge the gap between fundamental research and clinical applications. Her diverse background also underpins her leadership at DIVA Expertise, driving advancements in the understanding and application of adipose tissue research.

DIVA Expertise is a leading French biotech company specializing in applied research on human adipose tissue. Dr. Keophiphath co-founded DIVA with a strong desire to address critical public health challenges, including obesity, metabolic diseases, and the effects of an aging population. These issues, compounded by the rise of junk food consumption and malnutrition in resource-limited countries, underscored the need for innovative solutions. DIVA was established with a mission to drive meaningful advancements in biotechnology and global health.

The DIVA Biobank was developed to foster collaborative research and address the evolving needs of the industry. In response to economic constraints prompting industrial scientists to bring research in-house, DIVA proposed a solution by offering high-quality, customized resources through its biobank to ensure ongoing support for research efforts.

Transitioning from a service-based operation to a product-focused model required addressing logistical and operational challenges. DIVA partnered with reliable providers for communication, transportation, and bio-material handling to establish a secure and efficient system. Processes for packaging, international customs compliance, and quality assurance were implemented to maintain the integrity of all samples during shipment. Each sample is carefully tracked and meets rigorous quality standards, ensuring researchers receive reliable materials for their studies.

The biobank provides researchers with access to high-quality human material of European origin, ideal for diverse population studies, especially those focused on Caucasian-European cohorts. Customizable cohort options are also available to meet specific research needs, enabling the selection of various sample types (e.g., primay cells, RNA or proteins), or the creation of tailored cohorts (e.g., obese versus healthy groups) for precise and targeted testing.

All biobank activities comply with regulations set by the Ministry of Research and Higher Education. This ensures a level of quality, traceability, and ethical standards that effectively support research across pharmaceutical, nutraceutical, and cosmetic industries.

DIVA partnered with abm to combine their expertise in product development and research services. With abm’s strong reputation in bio-material supply, a local office in France, and scientific expertise, the collaboration was a natural fit. Together, this partnership provides integrated resources and services to advance research in cell biology and biotechnology.

Looking ahead, DIVA plans to expand internationally by establishing subsidiaries and production sites in new regions. With its biobank fully operational, DIVA aims to replicate this model globally to support research in resource-limited countries. Guided by its mission to promote accessible scientific progress, DIVA remains committed to driving meaningful advancements worldwide.

Learn more about DIVA on their website and stay updated on their journey by following them on LinkedIn.